Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Journal:

The New England Journal of Medicine

Published:

2025-10-18

DOI:

10.1056/nejmoa2510308

Affiliations:

23

Authors:

22

Go to article

Institutions	Authors	Share
Saitama Medical University International Medical Center, Japan	2.000000	0.09
AstraZeneca, United Kingdom (UK)	2.000000	0.09
The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom (UK)	1.000000	0.05
National Institute of Neoplastic Diseases (INEN), Peru	1.000000	0.05
Jilin Province Cancer Hospital, China	1.000000	0.05
University of Calgary (U of C), Canada	1.000000	0.05
Tata Medical Center (TMC), India	1.000000	0.05
Seoul National University Hospital (SNUH), South Korea	1.000000	0.05
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.05
St George Hospital (SGH), SESLHD, Australia	1.000000	0.05
Shanghai Chest Hospital, SJTU, China	1.000000	0.05
AstraZeneca Spain, Spain	1.000000	0.05
Oncologia Clínica Florianópolis, Brazil	1.000000	0.05
FSBI N.N. Petrov National Medical Research Center of Oncology, Russia	1.000000	0.05
University Hospital in Motol, Czech Republic	1.000000	0.05
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.05
Cancer Institute Hospital, JFCR, Japan	1.000000	0.05
Bradford Hill, Chile	1.000000	0.05
National Taiwan University (NTU), Taiwan	0.500000	0.02
Institute Gustave-Roussy (IGR), France	0.500000	0.02
National Taiwan University Hospital (NTUH), Taiwan	0.500000	0.02
University of Paris-Saclay, France	0.500000	0.02

Interested in Oncology and Carcinogenesis?